Gland Pharma Limited has officially reappointed Ms. Naina Lal Kidwai as an Independent Director. Following approval from shareholders via postal ballot, she will serve a second term of five consecutive years. Her new tenure is effective from May 17, 2026, and will run through May 16, 2031. The reappointment also includes an approved commission on profits as remuneration for her continued leadership and guidance on the Board.
Board Leadership Continuity
Gland Pharma Limited has confirmed the successful reappointment of Ms. Naina Lal Kidwai to its Board of Directors. Shareholders have overwhelmingly supported her continuation in the role of Independent Director for a second five-year term. This decision reflects the company’s commitment to maintaining experienced and expert leadership as it moves into the next phase of its growth cycle through 2031.
Distinguished Industry Expertise
Ms. Kidwai brings extensive global experience to the Gland Pharma Board. She currently holds leadership positions as the Chairman of Rothschild & Co India and serves as a Senior Advisor for several prominent private equity and venture capital firms, including Advent Private Equity and Lightspeed Venture Partners. Her career includes notable tenures as the head of HSBC India and as a past President of FICCI.
Focus on Sustainability and Governance
Beyond her corporate roles, Ms. Kidwai is highly regarded for her contributions to environmental, water, and sanitation initiatives. She is a published author and has served on numerous advisory boards, including those for the Harvard Business School and the World Economic Forum. Her ongoing commitment to sustainability, combined with her deep understanding of financial markets, continues to be a strategic asset for the company as it navigates complex global regulatory and industry landscapes.
Source: BSE
